JOP20180102A1 - مركب صيدلاني - Google Patents

مركب صيدلاني

Info

Publication number
JOP20180102A1
JOP20180102A1 JOP/2018/0102A JOP20180102A JOP20180102A1 JO P20180102 A1 JOP20180102 A1 JO P20180102A1 JO P20180102 A JOP20180102 A JO P20180102A JO P20180102 A1 JOP20180102 A1 JO P20180102A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical composition
relates
present
pharmaceutical compositions
improved stability
Prior art date
Application number
JOP/2018/0102A
Other languages
English (en)
Inventor
Malm Mattias
Britta Siekmann Dr
Nilsson Anders
Wisniewski Kazimierz
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20180102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of JOP20180102A1 publication Critical patent/JOP20180102A1/ar
Application granted granted Critical
Publication of JOP20180102B1 publication Critical patent/JOP20180102B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

يتعلق الإختراع الحالي بمركبات صيدلانية ذات إستقرارية مُحسنة.
JOP/2018/0102A 2010-09-30 2018-11-12 مركب صيدلاني JOP20180102B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JOP20180102A1 true JOP20180102A1 (ar) 2019-01-30
JOP20180102B1 JOP20180102B1 (ar) 2022-03-14

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2011/0297A JO3400B1 (ar) 2010-09-30 2011-09-28 مركب صيدلاني من كاربيتوسين
JOP/2018/0103A JOP20180103B1 (ar) 2010-09-30 2018-11-12 التركيب الصيدلاني للكاربيتوسين
JOP/2018/0102A JOP20180102B1 (ar) 2010-09-30 2018-11-12 مركب صيدلاني

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JOP/2011/0297A JO3400B1 (ar) 2010-09-30 2011-09-28 مركب صيدلاني من كاربيتوسين
JOP/2018/0103A JOP20180103B1 (ar) 2010-09-30 2018-11-12 التركيب الصيدلاني للكاربيتوسين

Country Status (27)

Country Link
US (4) US9566311B2 (ar)
EP (5) EP2621468B1 (ar)
JP (2) JP6038797B2 (ar)
KR (2) KR102102664B1 (ar)
CN (4) CN107412728A (ar)
AU (1) AU2011309762B2 (ar)
BR (2) BR122021001123B1 (ar)
CA (1) CA2812510A1 (ar)
CY (2) CY1119245T1 (ar)
DK (4) DK2621468T3 (ar)
ES (4) ES2637988T3 (ar)
FI (1) FI4374878T3 (ar)
HR (3) HRP20211969T1 (ar)
HU (4) HUE070972T2 (ar)
IL (3) IL225238B (ar)
JO (3) JO3400B1 (ar)
LT (3) LT4374878T (ar)
MX (3) MX352949B (ar)
NZ (1) NZ609719A (ar)
PL (4) PL3222272T3 (ar)
PT (4) PT3222272T (ar)
RS (3) RS66759B1 (ar)
RU (2) RU2604690C2 (ar)
SI (4) SI3222272T1 (ar)
SM (3) SMT202500165T1 (ar)
TW (6) TWI746951B (ar)
WO (1) WO2012042371A2 (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
MY192330A (en) * 2012-05-08 2022-08-17 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heapin or heparan sulphate and a uterotonic agent
CA2957224A1 (en) * 2014-09-19 2016-03-24 Ferring B.V. Method of treating prader-willi syndrome
JP6607509B2 (ja) 2014-10-01 2019-11-20 オキシトーン バイオサイエンス ビー．ブイ． 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
RU2719416C2 (ru) 2014-10-01 2020-04-17 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
HRP20231438T1 (hr) 2015-01-07 2024-06-07 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i načini uporabe
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
US10981955B2 (en) * 2017-08-11 2021-04-20 Ferring B.V. Method of manufacturing a pharmaceutical composition
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
WO2019169342A1 (en) 2018-03-01 2019-09-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
AU2019345313A1 (en) 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
CN112839632A (zh) 2018-09-20 2021-05-25 莱沃疗法公司 稳定的鼻内卡贝缩宫素制剂
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
CN113453661A (zh) * 2018-12-21 2021-09-28 艾瑞克有限公司 新组合物
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
CN114096267B (zh) 2019-05-22 2025-03-18 柏欧韦股份有限公司 特利加压素制剂
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
WO2021089554A1 (en) 2019-11-04 2021-05-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
PL4313106T3 (pl) 2021-03-26 2025-09-01 Ot4B Leczenie dysfagii
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
US12214010B2 (en) 2023-04-04 2025-02-04 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DE69736140T2 (de) 1997-11-18 2007-04-19 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1556068B1 (en) 2002-10-03 2010-08-18 Neuropharmacology Services, LLC Oxytocin for use in the treatment of Autism and Asperger's disorder
EP1599222B1 (en) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
EP1605894A2 (en) 2003-03-05 2005-12-21 PR Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
WO2009005352A1 (en) 2007-07-02 2009-01-08 Sime Darby Malaysia Berhad Frying fat composition
ES2319054B1 (es) * 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
HRP20140716T1 (hr) * 2008-03-31 2014-08-29 Ferring B.V. Analozi oksitocina
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Also Published As

Publication number Publication date
CY1124924T1 (el) 2023-01-05
IL225238B (en) 2018-07-31
RU2737264C2 (ru) 2020-11-26
ES2905561T3 (es) 2022-04-11
RU2016143751A (ru) 2018-12-18
HUE034367T2 (en) 2018-02-28
EP4374878A2 (en) 2024-05-29
WO2012042371A3 (en) 2013-04-04
HRP20211969T1 (hr) 2022-03-18
EP3246018A1 (en) 2017-11-22
PL2621468T3 (pl) 2017-11-30
ES3027637T3 (en) 2025-06-16
IL245328B (en) 2022-04-01
US20170106043A1 (en) 2017-04-20
TWI650134B (zh) 2019-02-11
JO3400B1 (ar) 2019-10-20
PL3246018T3 (pl) 2022-05-02
CN107080832A (zh) 2017-08-22
TW201729797A (zh) 2017-09-01
TWI532507B (zh) 2016-05-11
SMT202200034T1 (it) 2022-03-21
HUE070972T2 (hu) 2025-07-28
MX352949B (es) 2017-12-15
SI3222272T1 (sl) 2022-01-31
TWI680773B (zh) 2020-01-01
RS62873B1 (sr) 2022-02-28
RS66759B1 (sr) 2025-05-30
ES2902418T3 (es) 2022-03-28
TW202112389A (zh) 2021-04-01
JP6250770B2 (ja) 2017-12-20
LT2621468T (lt) 2017-11-27
BR112013007362B1 (pt) 2021-05-25
PT2621468T (pt) 2017-09-08
JOP20180103A1 (ar) 2019-01-30
EP3936117A1 (en) 2022-01-12
TWI661834B (zh) 2019-06-11
IL225238A0 (en) 2013-06-27
US9566311B2 (en) 2017-02-14
RU2016143751A3 (ar) 2020-01-16
CN107080832B (zh) 2021-05-07
DK3246018T3 (da) 2022-01-17
SMT202500165T1 (it) 2025-05-12
SI2621468T1 (sl) 2017-10-30
CY1119245T1 (el) 2018-02-14
HUE057187T2 (hu) 2022-04-28
IL245326B (en) 2021-04-29
HRP20171256T1 (hr) 2017-10-20
JOP20180103B1 (ar) 2022-03-14
HUE056835T2 (hu) 2022-03-28
BR122021001123B1 (pt) 2021-05-18
EP3222272A1 (en) 2017-09-27
EP4374878A3 (en) 2024-07-24
IL245328A0 (en) 2016-06-30
JP2017048226A (ja) 2017-03-09
CN104906032A (zh) 2015-09-16
PT4374878T (pt) 2025-05-02
MX390779B (es) 2025-03-21
US20130210746A1 (en) 2013-08-15
US20170106044A1 (en) 2017-04-20
TW201605465A (zh) 2016-02-16
TW201605466A (zh) 2016-02-16
CN107412728A (zh) 2017-12-01
LT4374878T (lt) 2025-04-25
JP2013543492A (ja) 2013-12-05
TWI750934B (zh) 2021-12-21
EP2621468A2 (en) 2013-08-07
SI4374878T1 (sl) 2025-06-30
DK4374878T3 (da) 2025-05-05
JOP20180102B1 (ar) 2022-03-14
NZ609719A (en) 2014-07-25
KR101919119B1 (ko) 2018-11-15
EP2621468B1 (en) 2017-06-14
JP6038797B2 (ja) 2016-12-07
KR102102664B1 (ko) 2020-04-22
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
AU2011309762A1 (en) 2013-04-04
CN103124554A (zh) 2013-05-29
DK2621468T3 (en) 2017-09-11
PL3222272T3 (pl) 2022-03-07
US20230124105A1 (en) 2023-04-20
ES2637988T3 (es) 2017-10-18
LT3222272T (lt) 2021-12-27
HRP20250382T1 (hr) 2025-05-23
FI4374878T3 (fi) 2025-05-16
CA2812510A1 (en) 2012-04-05
IL245326A0 (en) 2016-06-30
RU2013112666A (ru) 2014-11-10
WO2012042371A2 (en) 2012-04-05
MX2013003365A (es) 2013-07-29
RS56220B1 (sr) 2017-11-30
HK1246170A1 (en) 2018-09-07
PT3246018T (pt) 2022-01-13
EP4374878B1 (en) 2025-02-12
SMT201700420T1 (it) 2017-11-15
SI3246018T1 (sl) 2022-02-28
MX395271B (es) 2025-03-21
PL4374878T3 (pl) 2025-06-09
EP3246018B1 (en) 2021-11-03
TW201940188A (zh) 2019-10-16
AU2011309762B2 (en) 2014-07-17
TWI746951B (zh) 2021-11-21
DK3222272T3 (da) 2022-01-24
RU2604690C2 (ru) 2016-12-10
KR20130136467A (ko) 2013-12-12
EP3222272B1 (en) 2021-11-03
BR112013007362A2 (pt) 2016-07-12
KR20180123599A (ko) 2018-11-16

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
MX2012015188A (es) Composiciones de liberacion controlada con efecto de alimentos reducido.
MY173521A (en) Trpv4 antagonists
IN2014DN09346A (ar)
PH12013500386A1 (en) Pesticidal compositions
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
PH12013500360B1 (en) Pesticidal compositions
IN2015DN00960A (ar)
EA201590887A1 (ru) Композиция
MX348325B (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
MY149433A (en) Nutritional compositions containing punicalagins
MX2014002625A (es) Nuevas composiciones para la produccion de poliamidas coladas.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
TR201109160A2 (tr) Eplerenon içeren yeni farmasötik kompozisyonlar.
MX351789B (es) Nueva composicion para la preparación de poliamidas de fundido..
PH12014500531A1 (en) Anti-inflammatory compositions comprising malvidin - 3 - o - beta-glucoside and a propolis extract
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия
GB201005403D0 (en) Novel pharmaceutical compositions
TN2010000225A1 (en) Injectable liquid paracetamol formulation